

Why JYNARQUE® (tolvaptan)?
Push back the progression of your ADPKD with JYNARQUE
Tolvaptan is a recommended treatment by the KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD. The guidelines offer clear, research-based recommendations to help patients and doctors make informed decisions.
JYNARQUE slowed the decline of kidney function by
as seen in REPRISE, a 1-year clinical study of patients with
CKD stages 2 to 4, vs placebo*
Treatment effect: 1.3 mL/min/1.73 m2/year (95% Cl: 0.86-1.68, P<.0001).
-2.3 mL/min/1.73 m2/year with JYNARQUE vs -3.6 mL/min/1.73 m2/year with placebo.
Treatment effect: 1.3 mL/min/1.73 m2/year (95% Cl: 0.86-1.68, P<.0001).
-2.3 mL/min/1.73 m2/year with JYNARQUE vs -3.6 mL/min/1.73 m2/year with placebo.
as seen in TEMPO 3:4, a 3-year clinical study of patients
with CKD stages 1 to 3, vs placebo*
Treatment effect: 1.0 mL/min/1.73 m2/year (95% CI: 0.6-1.4, P<.001).
-2.7 mL/min/1.73 m2/year with JYNARQUE vs -3.7 mL/min/1.73 m2/year with placebo.
Treatment effect: 1.0 mL/min/1.73 m2/year (95% CI: 0.6-1.4, P<.001).
-2.7 mL/min/1.73 m2/year with JYNARQUE vs -3.7 mL/min/1.73 m2/year with placebo.
With JYNARQUE, help slow the progression of your disease—across CKD stages
JYNARQUE is appropriate for adults who are at risk for rapidly progressing ADPKD, throughout CKD stages 1 to 4
STAGES OF CKD
STAGES OF CKD

Patients taking JYNARQUE experienced less kidney pain
In a clinical trial of patients with ADPKD, at CKD stages 1 to 3, those taking JYNARQUE were likely to experience
fewer pain events
9.9% of patients taking JYNARQUE had a pain event vs 16.2% of those taking placebo
Patient images reflect their health status at the time the photo was taken. Morgan is a real patient and has been compensated by Otsuka America Pharmaceutical, Inc. for her time.
Talk to your nephrologist to see how you can slow the progression of your ADPKD today
CKD=chronic kidney disease; FDA=Food and Drug Administration; KDGIO=Kidney Disease Improving Global Outcomes.
*Kidney function was measured by the change in the average eGFR over time.